DV
Dividend Vision

ALNY — Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. (ALNY)

Total return is 3704.5% over the past 22.2 years, 2769.1 points ahead of SPY at 935.4%. Its deepest 1-year drawdown was 58.2%.

ALNY is a single-stock equity holding in Alnylam Pharmaceuticals, a biopharmaceutical company, rather than a diversified ETF. The holding does not currently pay dividends, resulting in a N/A distribution rate and no regular income distributions. This equity position appeals primarily to growth-oriented investors seeking exposure to the pharmaceutical sector, as it offers capital appreciation potential rather than yield-based income.

ALNY key facts

Asset type
Stock
Asset class
Equity
Inception date
05/28/2004
Distribution frequency
None
Last close
$228.65
Market cap
$30,595,454,976
Average volume
1525800.0
Beta
0.279
Payout ratio
0.0
P/E ratio
39.5588
Forward P/E
25.0
EPS
$5.78